Specimen:
Collect
- One Lavender (EDTA)
Also Acceptable:
- One Pink Top (EDTA)
Submit
- 4 mL (Min:2 mL) Whole blood in Lavender (EDTA). Submit Refrigerated.
Also Acceptable:
- 6 mL (Min:2 mL) Whole blood in Pink Top (EDTA). Submit Refrigerated.
Special Handling
- Variant analyzed: c.1601G>A (p.Arg534Gln), referred to as Factor V Leiden.
Rejection Criteria
- Shared samples - a separate sample must be collected for molecular testing (Testing for MTHFR, FACTOR V, and PT GENE MUTATION may be performed from same tube).
Stability
Ambient: Unacceptable; Refrigerated: 1 Month(s); Frozen: Unacceptable; Incubated: Unacceptable
Methodology
- Mass Spectrometry Coupled with End-Point PCR
Performed
Wednesday
Reported
1-7 Day(s)
CPT Codes
- 81241
Interpretive Data
General Reference Range : negative
Where appropriate, medical consultation and/or genetic counseling should be offered to patients to inform and explain the risk implications and genetic implications of these test results.
Patient DNA is assayed for the Factor V Leiden G1691A mutation by polymerase chain reaction (PCR) and MOLDI-TOF mass spectrometry technology. The product of PCR is detected on the Agena Bioscience MassARRAY system.
Other causes of activated protein C resistance and hereditary forms of venous thrombosis are not ruled out. The test result must be interpreted along with the patient's clinical history and other pertinent laboratory data.
Variant analyzed: c.1601G>A (p.Arg534Gln), referred to as Factor V Leiden.
Laboratory Developed Test (LDT). This test was developed and its performance characteristics determined by Interpath Laboratory in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Where appropriate, medical consultation and/or genetic counseling should be offered to patients to inform and explain the risk implications and genetic implications of these test results.
Patient DNA is assayed for the Factor V Leiden G1691A mutation by polymerase chain reaction (PCR) and MOLDI-TOF mass spectrometry technology. The product of PCR is detected on the Agena Bioscience MassARRAY system.
Other causes of activated protein C resistance and hereditary forms of venous thrombosis are not ruled out. The test result must be interpreted along with the patient's clinical history and other pertinent laboratory data.
Variant analyzed: c.1601G>A (p.Arg534Gln), referred to as Factor V Leiden.
Laboratory Developed Test (LDT). This test was developed and its performance characteristics determined by Interpath Laboratory in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.
Components
- 1152 - FACTOR V LEIDEN
Last Updated: May 8, 2025 @ 9:13 am
Disclaimer:
It is preferable to locate tests on the website and not rely on printed test information, which may soon be out of date. Updated test information can only be guaranteed by using this website.
